GT103
Advanced Stage Non-Small Cell Lung Cancer (NSCLC)
Phase 2Active
Key Facts
Indication
Advanced Stage Non-Small Cell Lung Cancer (NSCLC)
Phase
Phase 2
Status
Active
Company
About Grid Therapeutics
Grid Therapeutics is a private, clinical-stage biotech focused on discovering and developing novel tumor-specific antibody therapeutics. The company has a unique platform for isolating antibodies directly from human B cells and has advanced its lead candidate, GT103, into a Phase 2 investigator-sponsored trial in non-small cell lung cancer (NSCLC) in combination with pembrolizumab. While still pre-revenue, Grid is actively building its pipeline through internal R&D and external partnerships, such as a recent collaboration with Infinimmune, positioning itself in the competitive but high-potential field of cancer immunotherapy.
View full company profile